We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
Cap. Flow
-$1B
Cap. Flow %
-12.68%
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35

Top Buys

Rank Stock Value
1
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$194M
2
BBIO icon
BridgeBio Pharma
BBIO
+$68.7M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$68.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$62.1M
5
SWTX
SpringWorks Therapeutics
SWTX
+$52.6M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$116M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$100M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$90.4M
4
NVTA
Invitae Corporation
NVTA
+$87.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$87.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.08%
2 Financials 0.47%
3 Industrials 0.2%
4 Consumer Discretionary 0.02%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BFLY.WS
126
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$1.5M 0.02%
+233,333
New +$1.9M
RACE icon
127
Ferrari
RACE
$67.7B
$1.3M 0.02%
6,200
– –
EIGR
128
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.24M 0.02%
4,663
– –
VINCW
129
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$1.21M 0.02%
300,000
– –
SRRA
130
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.15M 0.01%
66,655
– –
SCPE.WS
131
DELISTED
SC Health Corporation Warrants, each whole warrant exercisable for one Class A ordinary share at an
SCPE.WS
$945K 0.01%
+500,000
New +$812K
PHVS icon
132
Pharvaris
PHVS
$2.28B
$755K 0.01%
+27,000
New +$849K
CEREW
133
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$573K 0.01%
+133,066
New +$602K
CVM icon
134
CEL-SCI Corp
CVM
$19.9M
$513K 0.01%
+1,123
New +$613K
SANA icon
135
Sana Biotechnology
SANA
$882M
$335K ﹤0.01%
+10,000
New +$326K
CMAX
136
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$242K ﹤0.01%
667
– –
ABCL icon
137
AbCellera Biologics
ABCL
$1.65B
– –
-20,000
Closed -$805K
ADAP
138
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-400,000
Closed -$2.16M
ANAB icon
139
AnaptysBio
ANAB
$1.54B
– –
-1,195,336
Closed -$25.7M
AQST icon
140
Aquestive Therapeutics
AQST
$454M
– –
-1,385,720
Closed -$7.41M
AVXL icon
141
Anavex Life Sciences
AVXL
$232M
– –
-780,007
Closed -$4.21M
BNR
142
Burning Rock Biotech
BNR
$93.9M
– –
-15,000
Closed -$3.46M
CRIS icon
143
Curis
CRIS
$9.73M
– –
-3,125
Closed -$10.2M
DYN icon
144
Dyne Therapeutics
DYN
$4.15B
– –
-400,000
Closed -$8.4M
GERN icon
145
Geron
GERN
$905M
– –
-13,461,538
Closed -$21.4M
IMVT icon
146
Immunovant
IMVT
$7.93B
– –
-1,400,000
Closed -$64.7M
LEGN icon
147
Legend Biotech
LEGN
$3.65B
– –
-25,000
Closed -$704K
LUNG icon
148
Pulmonx
LUNG
$52.4M
– –
-385,000
Closed -$26.6M
MASS icon
149
908 Devices
MASS
$312M
– –
-77,500
Closed -$4.41M
MRVI icon
150
Maravai LifeSciences
MRVI
$975M
– –
-350,000
Closed -$9.82M
3 4 5
6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.

  • Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
  • Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
  • Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
  • Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
  • Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
  • Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.